Queenan Anne Marie, Foleno Barbara, Gownley Colleen, Wira Ellyn, Bush Karen
Johnson & Johnson Pharmaceutical Research and Development, LLC, Raritan, New Jersey 08869, USA.
J Clin Microbiol. 2004 Jan;42(1):269-75. doi: 10.1128/JCM.42.1.269-275.2004.
Escherichia coli and Klebsiella pneumoniae isolates with extended-spectrum beta-lactamases (ESBLs) or AmpC cephalosporinases generally respond as predicted to NCCLS tests for ESBL production. However, inoculum size may affect MICs. The effect of inoculum level in clinical isolates expressing beta-lactamases were studied at inocula within 0.5 log unit of the standard inoculum, using broth microdilution methodology with ceftazidime, cefotaxime, cefepime, cefpodoxime, and aztreonam. Strains with TEM-1 or no beta-lactamases gave consistent MIC results with inocula of 10(5) and 10(6) CFU/ml. When the bacteria were screened for ESBL production and the lower inoculum was used, several strains with ESBLs, including CTX-M-10, TEM-3, TEM-10, TEM-12, TEM-6, SHV-18, and K1, gave false-negative results for one or more antimicrobial agents (MICs below the NCCLS screening concentration for detecting suspected ESBLs). When the higher inoculum was used, MICs of at least one antimicrobial agent increased at least fourfold in strains producing TEM-3, TEM-10, TEM-28, TEM-43, SHV-5, SHV-18, and K1. All antimicrobial agents showed an inoculum effect with at least one ESBL producer. Confirmatory clavulanate effects were seen for both inocula for all ESBL-producing strains with all antimicrobial agents tested, except for the CTX-M-10-producing E. coli with ceftazidime and the SHV-18-producing K. pneumoniae with cefotaxime. In kinetic studies, cefpodoxime and cefepime were hydrolyzed by ESBLs in a manner similar to that of cefotaxime. When total beta-lactamase activity and hydrolysis parameters were evaluated, however, no single factor was predictive of inoculum effects. These results indicate that the NCCLS screening and confirmation tests are generally predictive of ESBL production, but false-negative results can arise when a lower inoculum is used in testing.
携带超广谱β-内酰胺酶(ESBLs)或AmpC头孢菌素酶的大肠埃希菌和肺炎克雷伯菌分离株,对NCCLS的ESBLs检测通常有预期的反应。然而,接种量可能会影响最低抑菌浓度(MIC)。采用肉汤微量稀释法,使用头孢他啶、头孢噻肟、头孢吡肟、头孢泊肟和氨曲南,在标准接种量的0.5对数单位范围内,研究了接种量对表达β-内酰胺酶的临床分离株的影响。携带TEM-1或无β-内酰胺酶的菌株,接种量为10⁵和10⁶CFU/ml时,MIC结果一致。当对细菌进行ESBLs检测且使用较低接种量时,包括CTX-M-10、TEM-3、TEM-10、TEM-12、TEM-6、SHV-18和K1在内的几种携带ESBLs的菌株,对一种或多种抗菌药物出现假阴性结果(MIC低于NCCLS检测疑似ESBLs的筛选浓度)。当使用较高接种量时,产生TEM-3、TEM-10、TEM-28、TEM-43、SHV-5、SHV-18和K1的菌株中,至少有一种抗菌药物的MIC至少增加了四倍。所有抗菌药物对至少一种产ESBLs菌株均显示接种量效应。除了产CTX-M-10的大肠埃希菌对头孢他啶以及产SHV-18的肺炎克雷伯菌对头孢噻肟外,对于所有检测的抗菌药物,所有产ESBLs菌株的两种接种量均观察到确证性克拉维酸效应。在动力学研究中,头孢泊肟和头孢吡肟被ESBLs水解的方式与头孢噻肟相似。然而,当评估总β-内酰胺酶活性和水解参数时,没有单一因素可预测接种量效应。这些结果表明,NCCLS筛选和确证试验通常可预测ESBLs的产生,但检测时使用较低接种量可能会出现假阴性结果。